ArticleThe oncologist2025

First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.

Martin E Gutierrez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.